Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure

Abstract

Concern persists about the potential negative inotropic effects of calcium channel blockers in patients with severely depressed myocardial function. Therefore, intravenous diltiazem (100 to 200 micrograms/kg per min infusion) was administered for 40 minutes followed by oral diltiazem (90 to 120 mg/8 hours) for 24 hours to patients with advanced congestive heart failure (New York Heart Association class III to IV, mean ejection fraction 26 +/- 4 [SD]). Intravenous diltiazem (eight patients) increased cardiac index 20% (2.05 +/- 0.8 to 2.47 +/- 0.8 liters/min per m2, p less than 0.01), stroke volume index 50% (22 +/- 9 to 33 +/- 12 ml/m2, p less than 0.001) and stroke work index 27% (19 +/- 10 to 24 +/- 10 g-m/m2, p less than 0.05); while reducing heart rate 23% (97 +/- 18 to 75 +/- 11 beats/min, p less than 0.01), mean arterial pressure 18% (95 +/- 13 to 78 +/- 7 mm Hg) and pulmonary wedge pressure 34% (29 +/- 9 to 19 +/- 7 mm Hg), without altering maximal first derivative of left ventricular pressure (dP/dtmax). Oral diltiazem (seven patients) produced equivalent hemodynamic effects. Transient junctional arrhythmias were observed in three of eight patients with intravenous diltiazem and one of seven patients with oral diltiazem. It is concluded that intravenous and short-term oral diltiazem improve left ventricular performance and reduce myocardial oxygen demand by heart rate and afterload reduction without significantly depressing contractile function in severe congestive heart failure. Caution should be exercised to avoid potential adverse, drug-induced electrophysiologic effects in such patients.